Trade Report: The Hologic Inc. (NASDAQ:HOLX) Receives $42.60 Consensus Target Price from Analysts

The Hologic Inc. (NASDAQ:HOLX) Receives $42.60 Consensus Target Price from Analysts

Hologic Inc. (NASDAQ:HOLX) has earned a consensus rating of “Buy” from the nineteen ratings firms that are presently covering the stock. Six investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $42.60.

A number of brokerages recently issued reports on HOLX. Piper Jaffray Cos. set a $44.00 price target on Hologic and gave the company a “hold” rating in a report on Sunday, August 28th. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a report on Thursday, July 28th. BTIG Research reissued a “buy” rating and issued a $44.00 price objective on shares of Hologic in a report on Thursday, July 28th. Jefferies Group increased their price objective on Hologic from $42.00 to $43.00 and gave the company a “buy” rating in a report on Thursday, July 28th. Finally, Morgan Stanley increased their price objective on Hologic from $38.00 to $40.00 and gave the company an “equal weight” rating in a report on Thursday, July 28th.

In other news, Director Nancy Leaming sold 8,179 shares of the firm’s stock in a transaction on Thursday, July 21st. The stock was sold at an average price of $37.00, for a total value of $302,623.00. Following the completion of the transaction, the director now owns 67,140 shares in the company, valued at $2,484,180. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.84% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Glenmede Trust Co. NA boosted its position in shares of Hologic by 259.8% in the first quarter. Glenmede Trust Co. NA now owns 18,710 shares of the company’s stock worth $644,000 after buying an additional 13,510 shares in the last quarter. Ngam Advisors L.P. boosted its position in shares of Hologic by 11.7% in the first quarter. Ngam Advisors L.P. now owns 134,353 shares of the company’s stock worth $4,636,000 after buying an additional 14,115 shares in the last quarter. BlackRock Japan Co. Ltd boosted its position in shares of Hologic by 3.1% in the first quarter. BlackRock Japan Co. Ltd now owns 313,303 shares of the company’s stock worth $10,809,000 after buying an additional 9,312 shares in the last quarter. Marietta Investment Partners LLC purchased a new position in shares of Hologic during the first quarter worth $795,000. Finally, Acrospire Investment Management LLC purchased a new position in shares of Hologic during the first quarter worth $293,000. Institutional investors and hedge funds own 94.51% of the company’s stock.

Shares of Hologic (NASDAQ:HOLX) opened at 39.74 on Wednesday. Hologic has a one year low of $31.84 and a one year high of $41.66. The stock has a market cap of $11.02 billion, a price-to-earnings ratio of 43.81 and a beta of 1.00. The company has a 50-day moving average of $38.44 and a 200 day moving average of $36.22.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, July 27th. The company reported $0.51 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.48 by $0.03. The firm earned $717.40 million during the quarter, compared to the consensus estimate of $703.66 million. Hologic had a return on equity of 26.25% and a net margin of 9.39%. The firm’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.43 earnings per share. On average, equities analysts forecast that Hologic will post $1.94 earnings per share for the current fiscal year.

Related posts

Leave a Comment